Related Experiment Videos
Venlafaxine in social phobia
1Bowman Gray School of Medicine, Winston-Salem, NC, USA.
Psychopharmacology Bulletin
|January 1, 1995
Summary
Venlafaxine, an antidepressant, showed significant improvement in social phobia patients, especially those unresponsive to SSRIs. Further research is needed, but initial results suggest venlafaxine is a promising treatment for social anxiety disorder.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Social phobia is a common anxiety disorder causing significant impairment.
- High rates of comorbid depression are observed in social phobia patients.
- Antidepressant treatment is frequently indicated for social phobia.
Purpose of the Study:
- To evaluate the efficacy of venlafaxine in treating social phobia.
- To assess venlafaxine's potential in patients who did not respond to SSRIs.
Main Methods:
- An open-label trial involving 9 patients diagnosed with social phobia.
- Review of patient charts for treatment response and tolerability.
- Eight patients had prior treatment failure or intolerance to SSRIs.
Main Results:
- Eight out of nine patients experienced marked improvement with venlafaxine treatment.
- Venlafaxine demonstrated potential efficacy in patients refractory to SSRIs.
- A lower starting dose than typically recommended may be beneficial.
Conclusions:
- Venlafaxine may be an effective treatment option for social phobia.
- Larger, placebo-controlled studies are necessary to confirm these findings.
- Individualized dosing, potentially starting lower, could improve outcomes.